Direct renin inhibition: Promising treatment in renoprotection?

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 2, 2010, Pages 113-119

  Loriga, Giacomina ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Aliskiren; Chronic kidney disease; Kidney disease progression; Proteinuria; Renin angiotensin system; Treatment of hypertension Related target organ damage

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; RENIN; RENIN INHIBITOR; VALSARTAN; AMIDE; ANGIOTENSIN RECEPTOR; FUMARIC ACID DERIVATIVE;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG DOSE TITRATION; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DRUG EFFECTS; KIDNEY DISEASES; METABOLISM; PHYSIOLOGY; RAT; TOXICITY; TREATMENT OUTCOME;

AMIDES; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CHRONIC DISEASE; FUMARATES; HUMANS; KIDNEY DISEASES; RATS; RECEPTORS, ANGIOTENSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; ANGIOTENSIN RECEPTOR ANTAGONISTS;

EID: 77953804289     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010791515322     Document Type: Article

References (75)

1. Skeggs LT, Dorer FE, Kahn JR, Lentz KE, Levine M. Thebiochemistry of the renin-angiotensin system and its role inhypertension. Am J Med 1976; 60: 737-48.
2. Brewster UC, Perazella MA. Renin-angiotensin-aldosterone systemand the kidney: Effect on kidney disease. Am J Med 2004; 116(4):263-72.
3. Dzau VJ, Re R. Tissue angiotensin system in cardiovascularmedicine: A paradigm shift? Circulation 1994; 89: 493-8.
4. Garty H. Regulation of sodium permeability by aldosterone. Semin Nephrol 1992; 12: 24-9.
5. Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000; 15: 61-3.
6. Luft FC. Proinflammatory effects of angiotensin II and endothelin:Targets for progression of cardiovascular and renal disease. CurrOpin Nephrol Hypertens 2002; 11: 59-66.
7. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-convertingenzyme inhibition and renal protection in nondiabetic patients: Thedata of the meta analyses. J Am Soc Nephrol 2005; 16 (Suppl 1):S58-63.
8. Cravedi P, Ruggenenti P, Remuzzi G. Intensified inhibition ofrenin-angiotensin system: A way to improve renal protection. Curr Hypertens Rep 2007; 9(5): 430-6.
9. Hollenberg NK. Pharmacologic interruption of the rennin-angiotensin system and the kidney: Differential responses toangiotensin-converting enzyme and rennin inhibition. J Am SocNephrol 1999; 10 (Suppl 11): S239-42.
10. Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, et al. Aldosterone breakthrough during angiotensin II receptorblockade in hypertensive patients with diabetes mellitus. Am JHypertens 2007; 20(12): 1329-33.
11. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3(9): 486-92.
12. Feldman, D., Zelenkofske, S., Dinboeck, M., Prescott, M. Use of renin inhibitors in therapy. EP1977741 (2008).
13. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of the renin/prorenin receptor in angiotensin IIproduction and cellular responses to renin. J Clin Invest 2002; 109:1417-27.
14. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptidecorresponding to the handle region for non-proteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-35.
15. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, et al. Regression of nephropathy developed indiabetes by (Pro)renin receptor blockade. J Am Soc Nephrol 2007;18(7): 2054-61.
16. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin IIsuppression in humans by the orally active renin inhibitor Aliskiren(SPP100). Comparison with Enalapril. Hypertension 2002; 39(1):E1-8.
17. [17] Kushiro T, Itakura H, Abo Y. Aliskiren, a novel oral renininhibitor, provides dose-dependent efficacy and placebo-liketolerability in Japanese patients with hypertension. Hypertens Res 2006; 29(12): 997-1005.
18. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. AVOID Study Investigators. Aliskiren combined with losartan intype 2 diabetes and nephropathy. N Engl J Med 2008; 358(23):2433-46.
19. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren Trial in Type 2 Diabetes UsingCardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 2009; 24(5): 1663-71.
20. Erdos EG. Angiotensin I converting enzyme and the changes in ourconcepts through the years. Hypertension 1990; 16: 363-70.
21. nd ed. London, United Kingdom:Baillere Tindall 1998: 393-430.
22. Juknevicius I, Segal Y, Kren S. Aldosterone causes TGF-expression. J Am Soc Nephrol 2000; 11: 622A.
23. Hostetter TH, Rosemberg ME, Ibrahim HN, Juknevicius I. Aldosterone in renal disease. Curr Opin Nephro Hypertens 2001;10:105-10.
24. Wolf G, Mentzel S, Assmann KJM. Aminopeptidase A: A keyenzyme in the intrarenal degradation of angiotensin II. ExpNephrol 1997; 5: 364-9.
25. Gesualdo G, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, et al. Angiotensin IV stimulates plasminogenactivator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 1999; 56: 461-70.
26. Sealey JE, White RP, Laragh JH, Rubin AL. Plasma prorenin and renin in anephric patients. Circ Res 1977; 41(4 Suppl 2): 17-21.
27. Van Kesteren A., Danser AH, Derkx FH, Dekkers DH, Lamers JM, Saxena PR, et al. Mannose-6-phosphate receptor mediatedinternalization and activation of prorenin by cardiac cells. Hypertension 1997; 30: 1389-96.
28. Admiraal PJ, Van Kesteren CA, Danser AH, Derkx FH, Sluiter W, Schalekamp MA. Uptake and proteolytic activation of prorenin bycultured human endothelial cells. J Hypertens 1999; 17: 621-9.
29. Maru I, Ohta Y, Murata K, Tsukada Y. Molecular cloning and identification of N-Acyl-D-glucosamine 2-epimerase from porcinekidney as renin-binding protein. J Biol Chem 1996; 271: 16294-9.
30. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specificreceptor binding of renin on human mesangial cells in cultureincreases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50: 1897-903.
31. Nguyen G, Bouzhir L, Delarue F, Rondeau E, Sraer JD. Evidence of a renin receptor on human mesangial cells: Effects on PAI1 and cGMP. Nephrologie 1998; 19: 411-6.
32. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin IIproduction and cellular responses to renin. J Clin Invest 2002;109(11): 1417-27.
33. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 2003; 278: 22217-22.
34. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
35. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitorbenazepril on the progression of chronic renal insufficiency. TheAngiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-45.
36. The GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk ofterminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857-63.
37. Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascularoutcomes in patients with type 2 diabetes and nephropathy. N EnglJ Med 2001; 345: 861-9.
38. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on thedevelopment of diabetic nephropathy in patients with type 2diabetes. N Engl J Med 2001; 345: 870-8.
39. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin receptor antagonistirbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
40. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH. Theparadox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994; 45: 403-10.
41. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensinsystem and other antihypertensive drugs on renal outcomes:systematic review and meta-analysis. Lancet 2005; 366: 2026-33.
42. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-8.
43. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S. Aldosteronebreakthrough during therapy with angiotensin-converting enzymeinhibitors and angiotensin II receptor blockers in proteinuricpatients with immunoglobulin A nephropathy. Nephrology(Carlton) 2006; 11: 462-6.
44. Weber MA, Giles TD. Inhibiting the renin-angiotensin system toprevent cardiovascular diseases: Do we need a morecomprehensive strategy? Rev Cardiovasc Med 2006; 7: 45-54.
45. Nguyen G, Burckle CA. The (pro)renin receptor: Biology and functional significance. Bull Acad Natl Med 2004; 188: 621-8; discussion 628-29.
46. Veber, D.F., Boger, B.M. Renin inhibitory peptides. US4478826(1984).
47. Luly, J.R., Dellaria, J.F. Renin inhibiting compounds. US4652551(1987).
48. Hudspeth, J.P., Kaltenbronn, J.S., Lunney, E.A., Repine, J.T., Roark, W.H., Stier, M.A., Tinney, F. J., Woo, P.W.K., Nicolaides, E.D. Renin inhibitors. US4743585 (1988).
49. Hudspeth, J.P., Kaltenbronn, J.S., Repine, J.T., Woo, P.W.K. Renin inhibitors II. US4863905 (1989).
50. Hudspeth, J.P., Kaltenbronn, J.S., Repine, J.T., Roark, W.H., Stier, M.A. Renin inhibitors III. US4895834 (1990).
51. Doherty, A.M., Hudspeth, J.P., Kaltenbronn, J.S., Repine, J.T., Roark, W.H., Sircar, I., Tinney, F.J. Renin inhibitors IV.US5024994 (1991).
52. Dobe, D., Gallant, M., Grimm, L., Juteau, H., Laliberte, S., Wu, TYH. Renin inhibitors. US0063091 (2010).
53. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growthfactor-beta1 and matrix proteins through receptor-mediated,angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113.
54. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Itoh H. The(pro)renin receptor and the kidney. Semin Nephrol 2007; 27: 524-8.
55. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, et al. Slowly progressive, angiotensin II-independentglomerulosclerosis in human (pro)renin-receptor-transgenic rats. JAm Soc Nephrol 2007; 18: 1789-95.
56. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950-61.
57. Juillerat L, Nussberger J, Ménard J, Mooser V, Christen Y, Waeber B, et al. Determinants of angiotensin II generation duringconverting enzyme inhibition. Hypertension 1990; 16: 564-72.
58. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: Is there truly a benefit of addingan ACE inhibitor? Hypertension 2003; 41: 31-6.
59. Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, et al. Pharmacologic demonstration of thesynergistic effects of a combination of the renin Inhibitor aliskirenand the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126-33.
60. Fisher ND, Hollenberg NK. Renin inhibition: What are thetherapeutic opportunities? J Am Soc Nephrol 2005; 16: 592-9.
61. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treatinghypertension: Reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20: 587-97.
62. Loriga G, Vidili G, Ruggenenti P, Faedda R, Sanna M, Satta AE. Renal Hemodynamics and renoprotection. Nephron Clin Pract 2008; 110(4): C213-9.
63. Maibaum J, Feldman DL. Renin inhibitors as novel treatments forcardiovascular disease. Expert Opin Ther Patent 2003; 13: 589-603.
64. Wood JM, Maibaum J, Rahuel J. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem BiophysRes Commun 2003; 308: 698-705.
65. Finkelstein, N., Mittelman, A. Aliskiren monofumarate and processes for preparation thereof. US20100029774 (2010).
66. Satlin, A. Renin inhibitors for the treatment of hypertension. US0062395 (2009).
67. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacyand sustained 24-hour blood pressure control in patients withhypertension. J Am Coll Cardiol 2007; 49: 1157-63.
68. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor,provide dose-dependent antihypertensive efficacy and placebo-liketolerability in hypertensive patients. Circulation 2005; 111: 1012-8.
69. Weir MR, Bush C, Anderson DR, Zhang J, Keefe DL, Satlin A. Antihypertensive efficacy, safety and tolerability of the oral directrenin inhibitor aliskiren in patients with hypertension: A pooledanalysis. J Am Soc Hypertens 2007; 1: 264-77.
70. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacyand safety of combined use of aliskiren and valsartan in patientswith hypertension: A randomized, double-blind trial. Lancet 2007;370: 221-9.
71. Chrysant SG, Murray AV, Hoppe UC, Hoppe UC, Dattani D, Patel S, et al. Long-term safety, tolerability and efficacy of aliskiren incombination with valsartan in patients with hypertension: A 6month interim analysis. Curr Med Res Opin 2008; 24: 1039-47.
72. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Renal effect of aliskiren compared with and incombination with irbesartan in patients with type 2 diabetes,hypertension, and albuminuria. Diabetes Care 2009; 32(10): 1873-9.
73. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy resultsin the greatest and the least blood pressure lowering in patientswith high- and low-baseline PRA levels, respectively. Am JHypertens 2009; 22(9): 954-7.
74. Scaley JE, Laragh JH. Aliskiren fails to lower blood pressure inpatients who have either low PRA levels or whose PRA fallsinsufficiently or reactively rises. Am J Hypertens 2009; 22(1): 112-21.
75. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104.